MedTrace Logo

Dyskinesia

Disease

Related News

Doctors Implant Dopamine-Producing Stem Cells in Parkinson's Patients in Groundbreaking Trial

Doctors are implanting lab-grown stem cells into Parkinson's patients' brains in a groundbreaking clinical trial to restore dopamine production. The FDA has granted the Phase 1 REPLACE trial fast-track designation, testing iPSC-derived dopamine-producing cells in 12 patients with moderate to severe Parkinson's. Researchers will monitor participants for up to five years to assess motor function restoration and potential side effects.

Related Clinical Trials

NCT ID Title Status Phase
NCT06967727

Registry and Natural History of Epilepsy-Dyskinesia Syndromes

 RECRUITING
NCT05206513

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

 COMPLETED PHASE3
NCT02439125

A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients

 UNKNOWN PHASE2
NCT02274766

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

 COMPLETED PHASE3
NCT02202551

Open-Label Safety Study of ADS-5102 in PD Patients With LID

 COMPLETED PHASE3
NCT02136914

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

 COMPLETED PHASE3
NCT01937078

Famotidine for Levodopa-induced Dyskinesia in PD

 COMPLETED PHASE2
NCT01767129

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

 COMPLETED PHASE2
NCT01429207

Capturing Parkinson's Disease Medication Side Effects During Daily Activities

 COMPLETED
NCT01397422

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

 COMPLETED PHASE2/PHASE3